WO2005087721A2 - Compounds as inhibitors of hepatitis c virus ns3 serine protease - Google Patents
Compounds as inhibitors of hepatitis c virus ns3 serine protease Download PDFInfo
- Publication number
- WO2005087721A2 WO2005087721A2 PCT/US2005/005772 US2005005772W WO2005087721A2 WO 2005087721 A2 WO2005087721 A2 WO 2005087721A2 US 2005005772 W US2005005772 W US 2005005772W WO 2005087721 A2 WO2005087721 A2 WO 2005087721A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- mmol
- group
- hcv
- Prior art date
Links
- 0 CCC[C@@](*C)(*C(C)C)[C@](*)N Chemical compound CCC[C@@](*C)(*C(C)C)[C@](*)N 0.000 description 30
- GNOINTWAQCDFPM-VIFPVBQESA-N CC(C)(C)C[C@@H](CN(C)S(C)(=O)=O)NC Chemical compound CC(C)(C)C[C@@H](CN(C)S(C)(=O)=O)NC GNOINTWAQCDFPM-VIFPVBQESA-N 0.000 description 1
- DKUJTDHTCXHKNU-NSHDSACASA-N CC(C)(C)C[C@@H](CN(C)S(c1ccc[s]1)(=O)=O)N[IH]C Chemical compound CC(C)(C)C[C@@H](CN(C)S(c1ccc[s]1)(=O)=O)N[IH]C DKUJTDHTCXHKNU-NSHDSACASA-N 0.000 description 1
- TVHUNPWBPHTQOM-SNVBAGLBSA-N CC(C)(C)[C@@H](CN(C)S(C1CC1)(=O)=O)NC Chemical compound CC(C)(C)[C@@H](CN(C)S(C1CC1)(=O)=O)NC TVHUNPWBPHTQOM-SNVBAGLBSA-N 0.000 description 1
- ZJEUMTQAOGUSMM-SECBINFHSA-N CC(C)(C)[C@@H](CN(C)S(N(C)C)(=O)=O)N=C=O Chemical compound CC(C)(C)[C@@H](CN(C)S(N(C)C)(=O)=O)N=C=O ZJEUMTQAOGUSMM-SECBINFHSA-N 0.000 description 1
- DFHGJXKLQBLQTP-SNVBAGLBSA-N CC(C)S(N(C)C[C@H](C(C)(C)C)NC)(=O)=O Chemical compound CC(C)S(N(C)C[C@H](C(C)(C)C)NC)(=O)=O DFHGJXKLQBLQTP-SNVBAGLBSA-N 0.000 description 1
- PFYPDUUXDADWKC-UHFFFAOYSA-N CC(C)c1ccccn1 Chemical compound CC(C)c1ccccn1 PFYPDUUXDADWKC-UHFFFAOYSA-N 0.000 description 1
- PUACTIIESPYWSI-UHFFFAOYSA-N CC(C)c1cnccc1 Chemical compound CC(C)c1cnccc1 PUACTIIESPYWSI-UHFFFAOYSA-N 0.000 description 1
- PZERUHNFRQLCFQ-RRKGBCIJSA-N CCC(C)[C@@H](CN(C)S(c1ccc[s]1)(=O)=O)NC Chemical compound CCC(C)[C@@H](CN(C)S(c1ccc[s]1)(=O)=O)NC PZERUHNFRQLCFQ-RRKGBCIJSA-N 0.000 description 1
- OIFGOYXLBOWNGQ-UHFFFAOYSA-N CCCC(C(C(O)=O)O)N Chemical compound CCCC(C(C(O)=O)O)N OIFGOYXLBOWNGQ-UHFFFAOYSA-N 0.000 description 1
- BZQIARROPFRNCP-UHFFFAOYSA-N CCCC(C(C(O)=O)O)[N+]([O-])=O Chemical compound CCCC(C(C(O)=O)O)[N+]([O-])=O BZQIARROPFRNCP-UHFFFAOYSA-N 0.000 description 1
- YYUUOEQXJGQPIS-UHFFFAOYSA-N CCCC(CN)NC Chemical compound CCCC(CN)NC YYUUOEQXJGQPIS-UHFFFAOYSA-N 0.000 description 1
- GHNDHWSNABTWLF-UHFFFAOYSA-N CCS(N(C)CC1(CCCCC1)NC)=O Chemical compound CCS(N(C)CC1(CCCCC1)NC)=O GHNDHWSNABTWLF-UHFFFAOYSA-N 0.000 description 1
- NLKQDTLLVNCQJZ-UHFFFAOYSA-N CNC(CC1CC1)C(C(NCC=C)=O)O Chemical compound CNC(CC1CC1)C(C(NCC=C)=O)O NLKQDTLLVNCQJZ-UHFFFAOYSA-N 0.000 description 1
- CQTGPSNGXGTVNE-UHFFFAOYSA-N CNC1(CN(C)S(C)(=O)=O)CCCCC1 Chemical compound CNC1(CN(C)S(C)(=O)=O)CCCCC1 CQTGPSNGXGTVNE-UHFFFAOYSA-N 0.000 description 1
- BLYURPPZTULSML-UHFFFAOYSA-N CS(NCC1(CCCCC1)NC(OCc1ccccc1)=O)(=O)=O Chemical compound CS(NCC1(CCCCC1)NC(OCc1ccccc1)=O)(=O)=O BLYURPPZTULSML-UHFFFAOYSA-N 0.000 description 1
- ZVDZIFWZKMQAGP-OAUWFCSDSA-N C[C@H](C[C@H]1C(NCC(C(NCC=C)=O)=O)=O)CN1C([C@H](C1CCCCC1)NC(N[C@H](CN(C)SN(C)C)C(C)(C)C)=O)=O Chemical compound C[C@H](C[C@H]1C(NCC(C(NCC=C)=O)=O)=O)CN1C([C@H](C1CCCCC1)NC(N[C@H](CN(C)SN(C)C)C(C)(C)C)=O)=O ZVDZIFWZKMQAGP-OAUWFCSDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel hepatitis C virus ("HCV”) protease inhibitors, pharmaceutical compositions containing one or more such inhibitors, methods of preparing such inhibitors and methods of using such inhibitors to treat hepatitis C and related disorders.
- HCV hepatitis C virus
- This invention additionally discloses novel compounds as inhibitors of the HCV NS3/NS4a serine protease.
- Hepatitis C virus is a (+)-sense single-stranded RNA virus that has been implicated as the major causative agent in non-A, non-B hepatitis (NANBH), particularly in blood-associated NANBH (BB-NANBH) (see, International Patent Application Publication No. WO 89/04669 and European Patent Application Publication No. EP 381 216).
- NANBH is to be distinguished from other types of viral-induced liver disease, such as hepatitis A virus (HAV), hepatitis B virus (HBV), delta hepatitis virus (HDV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), as well as from other forms of liver disease such as alcoholism and primary biliar cirrhosis.
- HCV hepatitis A virus
- HBV hepatitis B virus
- HDV delta hepatitis virus
- CMV cytomegalovirus
- EBV Epstein-Barr virus
- This approximately 3000 amino acid polyprotein contains, from the amino terminus to the carboxy terminus, a nucleocapsid protein (C), envelope proteins (E1 and E2) and several non-structural proteins (NS1 , 2, 3, 4a, 5a and 5b).
- NS3 is an approximately 68 kda protein, encoded by approximately 1893 nucleotides of the HCV genome, and has two distinct domains: (a) a serine protease domain consisting of approximately 200 of the N-terminal amino acids; and (b) an RNA-dependent ATPase domain at the C- terminus of the protein.
- the NS3 protease is considered a member of the chymotrypsin family because of similarities in protein sequence, overall three- dimensional structure and mechanism of catalysis.
- Other chymotrypsin-like enzymes are elastase, factor Xa, thrombin, trypsin, plasmin, urokinase, tPA and PSA.
- the HCV NS3 serine protease is responsible for proteolysis of the 5 polypeptide (polyprotein) at the NS3/NS4a, NS4a/NS4b, NS4b/NS5a and NS5a/NS5b junctions and is thus responsible for generating four viral proteins during viral replication. This has made the HCV NS3 serine protease an attractive target for antiviral chemotherapy.
- the inventive compounds can inhibit such protease. They also can modulate the processing of hepatitis C
- HCV virus 10 virus polypeptide. It has been determined that the NS4a protein, an approximately 6 kda polypeptide, is a co-factor for the serine protease activity of NS3. Autocleavage of the NS3/NS4a junction by the NS3/NS4a serine protease occurs intramolecularly (Le., cis) while the other cleavage sites are processed
- Cys- ⁇ Thr substitution at NS3/NS4a is postulated to account for the requirement of cis rather than trans processing at this junction. See, e.g., Pizzi et al. (1994) Proc. Natl. Acad. Sci. (USA) _9_l:888-892, Failla et al. (1996) Folding & Design 1:35-42.
- the NS3/NS4a cleavage site is also more tolerant of mutagenesis than the other sites. See, e.g., Kollykhalov et al.
- HCV has been implicated in cirrhosis of the liver and in induction of hepatocellular carcinoma.
- the prognosis for patients suffering from HCV 15 infection is currently poor.
- HCV infection is more difficult to treat than other forms of hepatitis due to the lack of immunity or remission associated with HCV infection.
- Current data indicates a less than 50% survival rate at four :. years post cirrhosis diagnosis..
- the present invention provides a novel class of inhibitors of the HCV protease, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment or prevention of HCV or amelioration of one or more of the symptoms of hepatitis C using one or more such compounds or one or more such formulations. Also provided are methods of modulating the interaction of an HCV polypeptide with HCV protease. Among the compounds provided herein, compounds that inhibit HCV NS3/NS4a serine protease activity are preferred.
- the present invention discloses compounds, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers and racemates of said compounds, or a pharmaceutically acceptable salt, solvate or ester of said compounds, said compounds having the having the general structure shown in structural Formula 1 :
- R 1 is H, OR 8 , NR 9 R 10 , or CHR 9 R 10 , wherein R 8 , R 9 and R 10 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, heterocyclyl-, arylalkyl-, and heteroarylalkyl; A and M can be the same or different, each being independently selected from R, NR 9 R 10 , SR, S0 2 R, and halo; or A and M are connected to each other such that the moiety: ⁇ L— —B X ⁇ > shown above in Formula I (i.e., M-L-E-A taken together) forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membere
- cycloalkyl alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-; or alternately R and R' in NRR' are connected to each other such that NR 9 R 10 forms a four to eight-membered heterocyclyl; .
- Y 30 and Y 31 are selected from
- u is a number 0-6;
- X is selected from O, NR 15 , NC(0)R 16 , S, S(O) and S0 2 ;
- G is NH or O; and R 15 , R 16 , R 17 , R 8 , R 19 , Ti, T 2 , T 3 and T 4 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or alternately, R 17 and R 18 are connected to each other to form a three to eight-membered cycloalkyl or heterocyclyl;
- each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkyl, aryl, heteroaryl, alkylsulfonamido, arylsulfonamido, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonyiamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano, and nitro.
- a and M are connected to each other such that the moiety:
- Formula I forms either a three, four, six, seven or eight- membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten- membered aryl, or a five to ten-membered heteroaryl" can be illustrated in a non-limiting matter as follows.
- a and M are connected such that the moiety:
- Formula I forms a six -membered cycloalkyl (cyclohexyl), Formula I can be depicted as:
- M-L-E-A take together are connected to form a three, four, seven or eight- membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten- membered aryl, or a five to ten-membere heteroaryl.
- preferred alkyl is made of one to ten carbon atoms
- preferred alkenyl or alkynyl is made of two to ten carbon atoms
- preferred cycloalkyl is made of three to eight carbon atoms
- preferred heteroalkyl, heteroaryl or heterocycloalkyl (heterocyclyl) has one to six oxygen, nitrogen, sulfur, or phosphorus atoms.
- the compounds represented by Formula I can be useful for treating diseases such as, for example, HCV, HIV, AIDS (Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C virus (HCV) protease, preventing HCV, or ameliorating one or more symptoms of hepatitis C.
- HCV hepatitis C virus
- Such modulation, treatment, prevention or amelioration can be done with the inventive compounds as well as with pharmaceutical compositions or formulations comprising such compounds.
- HCV protease may be the NS3 or NS4a protease.
- the inventive compounds can inhibit such protease.
- R 1 is NR 9 R 10
- R 9 is H
- R 10 is H
- R 14 wherein R 14 is H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl- heteroaryl, aryl-alkyl, alkenyl, alkynyl or heteroaryl-alkyl.
- R 14 is selected from the group consisting of:
- R 2 is selected from the group consisting ofthe following moieties:
- R 3 is selected from the group consisting of:
- R 31 is OH or O-alkyl
- R 32 is H, C(0)CH 3 , C(0)OtBu or C(0)N(H)tBu.
- R 3 is selected from the group consisting of the following moieties:
- G is NH.
- Y is selected from the following moieties:
- Y /3 J 2 Z is selected from the group consisting of:
- Ti and T 2 can be the same or different, each being independently selected from the group consisting of:
- T 5 and T ⁇ can be the same or different, each being independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl; or the moiety: 1" "tX X taken together represents
- T 3 and T 4 can be the same or different, each being independently selected from: or T 3 and T 4 taken together may form part of a four to seven membered heterocydic ring; in other words, the moiety T3-N-C-T4 may form part of a four to seven membered heterocydic ring. In another embodiment, the moiety:
- the moiety is selected from the following structures:
- R 1 is NHR 14 , where R 14 is selected from the group consisting of:
- R >2 is selected from the group consisting ofthe following moieties:
- R 3 is selected from the group consisting of the following moieties:
- Y is selected from the group consisting of: o o
- alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain.
- “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
- substituted alkyl means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , -N(alkyl) 2 , carboxy and -C(0)0- alkyl.
- alkyl groups include methyl, ethyl, n- propyl, isopropyl and t-butyl.
- alkenyl means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain.
- “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- substituted alkenyl means that the alkenyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl).
- suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n- pentenyl, octenyl and decenyl.
- Alkynyl means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
- Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
- Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.
- “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3- methylbutynyl.
- substituted alkynyl means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
- Aryl means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
- Suitable aryl groups include phenyl and naphthyl.
- Heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms.
- the "heteroaryl” can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
- a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
- Non- limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyri
- heteroaryl also'refer ⁇ to partially saturated heteroaryl moieties such as, for example, tetra ydroisoquinolyl, tetrahydroquinolyl and the like.
- “Aralkyl” or “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2- phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
- Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non- limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
- Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
- Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like.
- "Halogen” or “halo” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
- Ring system substituent means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system.
- Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio
- Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system.
- Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH 3 ) 2 - and the like which form moieties such as, for example:
- Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
- Preferred heterocyclyls contain about 5 to about 6 ring atoms.
- the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
- Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like; such protections are also considered part of this invention.
- the heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like. It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:
- Alkynylalkyl means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
- Heteroaralkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group.
- Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl.
- the bond to the parent moiety is through the alkyl.
- "Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined.
- Preferred hydroxyalkyls contain lower alkyl.
- suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
- “Acyl” means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described.
- the bond to the parent moiety is through the carbonyl.
- Preferred acyls contain a lower alkyl.
- Non- limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
- “Aroyl” means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
- suitable groups include benzoyl and 1- naphthoyl.
- Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.
- suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parents moiety is through the ether oxygen.
- Aryloxy means an aryl-O- group in which the aryl group is as previously described.
- suitable aryloxy groups include phenoxy and naphthoxy.
- the bond to the parent moiety is through the ether oxygen.
- Aralkyloxy means an aralkyl-O- group in which the aralkyl group is as previously described.
- suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
- Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio.
- the bond to the parent moiety is through the sulfur.
- Arylthio means an aryl-S- group in which the aryl group is as previously described.
- suitable arylthio groups include phenylthio and naphthylthio.
- the bond to the parent moiety is through the sulfur.
- Aralkylthio means an aralkyl-S- group in which the aralkyl group is as previously described.
- Non-limiting example of a suitable aralkylthio group is benzylthio.
- the bond to the parent moiety is through the sulfur.
- Alkoxycarbonyl means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
- Aryloxycarbonyl means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
- Aralkoxycarbonyl means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl.
- alkylsulfonyl means an alkyl-S(0 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl.
- the bond to the parent moiety is through the sulfonyl.
- Arylsulfonyl means an aryl-S(0 2 )- group. The bond to the parent moiety is through the sulfonyl.
- substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound.
- isolated or “in isolated form” for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
- purified or “in purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan. It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atom(s) to satisfy the valences.
- protecting groups When a functional group in a compound is termed "protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction.
- Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New Yor . •" ' .-.-
- any variable e.g., aryl, heterocycle, R 2 , etc.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Prodrugs and solvates of the compounds of the invention are also contemplated herein.
- the term "prodrug”, as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of Formula 1 or a salt and/or solvate thereof.
- prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S.
- Solvate means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate” is a solvate wherein the solvent molecule is H 2 0.
- Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the CDK(s) and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
- the compounds of Formula 1 can form salts which are also within the scope of this invention. Reference to a compound of. Formula 1 herein is understood to include reference to salts thereof, unless otherwise indicated.
- salts when a compound of Formula 1 contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein.
- Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula 1 may be formed, for example, by reacting a compound of Formula 1 with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonat.es, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with arnino acids such as arginine,- lysine and the like:
- Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g: methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
- esters of the present compounds include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, dialkyl, or Ct ⁇ alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphon
- the phosphate esters may be further esterified by, for example, a C ⁇ o alcohol or reactive derivative thereof, or by a 2,3-di (C 6 - 24 )acyl glycerol.
- Compounds of Formula 1 , and salts, solvates and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
- All stereoisomers for example, geometric isomers, optical isomers and the like
- the present compounds including those ofthe salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs
- those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- the use ofthe terms "salt”, “solvate” "prodrug” and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs ofthe inventive compounds.
- polymorphic forms of the compounds of Formula I, and of the salts, solvates and prodrugs ofthe compounds of Formula I, are intended to be included in the present invention. It is to be understood that the utility ofthe compounds of Formula 1 for the therapeutic applications discussed herein is applicable to each compound by itself or to the combination or combinations of one or more compounds of Formula 1 as illustrated, for example, in the next immediate paragraph. The same understanding also applies to pharmaceutical composition(s) comprising such compound or compounds and method(s) of treatment involving such compound or compounds.
- the compounds according to the invention can have pharmacological properties; in particular, the compounds of Formula 1 can be inhibitors of HCV protease, each compound by itself or one or more compounds of Formula 1 can be combined with one or more compounds selected from within Formula 1.
- the compound(s) can be useful for treating diseases such as, for example, HCV, HIV, (AIDS, Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C virus (HCV) protease, preventing HCV, or ameliorating one or more symptoms of hepatitis C.
- HCV hepatitis C virus
- the compounds of Formula 1 may be used for the manufacture of a medicament to treat disorders associated with the HCV protease, for example, the method comprising bringing into intimate contact a compound of Formula 1 and a pharmaceutically acceptable carrier.
- this invention provides pharmaceutical compositions comprising the inventive compound or compounds as an active ingredient.
- the pharmaceutical compositions generally additionally comprise at least one pharmaceutically acceptable carrier diluent, excipient or carrier (collectively referred to herein as carrier materials). Because of their HCV inhibitory activity, such pharmaceutical compositions possess utility in treating hepatitis C and related disorders.
- the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive compounds as an active ingredient.
- the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e.
- the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ettiyl alcohol (liquid forms) and the like.
- any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ettiyl alcohol (liquid forms) and the like.
- suitable binders, lubricants, disintegrating agents and coloring agents m y also be incorporated in the mixture.
- Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition.
- Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
- lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the lil e.
- Disintegrants include starch, methylcellulose, guar gum and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate.
- compositions of the present indention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e. HCV inhibitory activity and the like.
- Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
- Liquid form preparations include solutions, suspensions and emulsions.
- Liquid form preparations may also include solutions for intranasal administration.
- Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
- a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
- a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing.
- the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
- Such liquid forms include solutions, suspensions and emulsions.
- the compounds of the invention may also be deliverable transdermally.
- the transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
- the compounds of the invention may also be administered orally, intravenously, intranasally or subcutaneously.
- the compounds of the invention may also comprise preparations which are in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., ah effective amount to achieve the desired purpose.
- the quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 1.0 milligram to about 1 ,000 milligrams, preferably from about 1.0 to about 950 milligrams, more preferably from about 1.0 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application.
- the actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.
- the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician.
- a generally recommended daily dosage regimen for oral administration may range from about 1.0 milligram to about 1 ,000 milligrams per day, in single or divided doses.
- Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients.
- Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
- Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents.
- the tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
- Oral gel- refers to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.
- Powder for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.
- Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose.
- the amount of diluent in the composition can range from about 10 tb about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.
- Disintegrant - refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments.
- Suitable disintegrants include starches; "cold water soluble” modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures.
- the amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.
- Binder - refers to substances that bind or "glue” powders together ⁇ and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starchtes derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate.
- the amount of binder in the composition an range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.
- Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear.
- Suitable lubricants include metall ⁇ c ⁇ p • • stearates such as magnesium stearate, calcium stearate or potassium - P. - . stearate; stearic acid; high melting point waxes; and water soluble lubrica nts ..
- Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts ofthe tablet press.
- the amount of lubricant in the composition can range from about 0.2 to about 5% by weight ofthe composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.
- Glident - material that prevents caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc.
- the amount of glident in the composition can range from about 0.1% to about 5% by weight ofthe total composition, preferably from about 0.5 to about 2% by weight.
- Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide.
- the amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.
- Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control. Conventional methods for preparing tablets are known.
- Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures. Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.
- Another embodiment ofthe invention discloses the use of the inventive compounds or pharmaceutical compositions disclosed above for treatment of diseases such as, for example, hepatitis C and the like.
- the method comprises administering a therapeutically effective amount of the inventive compound or pharmaceutical composition to a patient having such a disease or diseases and in need of such a treatment.
- the compounds of the invention may be used for the treatment of HCV in humans in moriotherapy mode or in a combination therapy (e.g., dual combination, triple combination etc.) mode such as, for example, in combination with antiviral and/or immunomodulatory agents.
- a combination therapy e.g., dual combination, triple combination etc.
- antiviral and/or immunomodulatory agents examples include Ribavirin (from Schering-Plough Corporation, Madison, New Jersey) and LevovirinTM (from ICN Pharmaceuticals, Costa Mesa, California), VP 50406TM (from Viropharma, Incorporated, Exton, Pennsylvania), ISIS 14803TM (from ISIS Pharmaceuticals, Carlsbad, California), HeptazymeTM (from Ribozyme Pharmaceuticals, Boulder, Colorado), VX 497TM (from Vertex Pharmaceuticals, Cambridge, Massachusetts), ThymosinTM (from SciClone Pharmaceuticals, San Mateo, California), MaxamineTM (Maxim Pharmaceuticals, San Diego, California), mycophenolate mofetil (from Hoffman-LaRoche, Nutley, New Jersey), interferon (such as, for example, interferon-alpha, PEG-interferon alpha conjugates) and the like.
- Ribavirin from Schering-Plough Corporation, Madison, New Jersey
- LevovirinTM from ICN Pharmaceuticals, Costa Mesa, California
- PEG- interferon alpha conjugates are interferon alpha molecules covalently attached to a PEG molecule.
- Illustrative PEG-interferon alpha conjugates include interferon alpha-2a (RoferonTM, from Hoffman La-Roche, Nutley, New Jersey) in the form of pegylated interferon alpha-2a (e.g., as sold under the trade name PegasysTM), interferon alpha-2b (IntronTM, from Schering-Plough Corporation) in the form of pegylated interferon alpha-2b (e.g., as sold under the trade name PEG-lntronTM), interferon alpha-2c (Berofor AlphaTM, from Boehringer Ingelheim, Ingelheim, Germany) or consensus interferon as defined by determination of a consensus sequence of naturally occurring interferon alphas (InfergenTM, from Amgen, Thousand Oaks, California).
- the invention includes tautomers, rotamers, enantiomers and other stereoisomers of the inventive compounds also.
- inventive compounds may exist in suitable isomeric forms. Such variations are contemplated to be within the scope of the invention.
- Another embodiment of the invention discloses a method of making the compounds disclosed herein.
- the compounds may be prepared by several techniques known in the art. Illustrative procedures are outlined in the , following reaction schemes. The illustrations should not be construed to limit the scope of the invention which is defined in the appended claims. Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.
- NMM N-Methylmorpholine ADDP: 1 ,1'-(Azodicarbobyl)dipiperidine
- Phg Phenylglycine • ⁇ ,
- Me Methyl HATU: 0-(7-azabenzotriazol-1 -yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
- DMAP 4-N,N-Dimethylaminopyridine
- Bop Benzotriazol-1-yl-oxy-tris(dimethylamino)hexafluorophosphate
- PCC Pyridiniumchlorochromate
- the hydrochloride salt 1.13 was converted to the 4- nitrophenyl carbamate 1.15 by reaction with 4-nitrophenyl chloroformate. Subsequent treatment with an amine (or amine hydrochloride salt) of choice provided the target compound 1.14.
- the dipeptide hydrochloride salt 1.04 was converted to the 4-nitrophenyl carbamate as described above. Treatment with an amine (or amine hydrochloride salt) of choice provided the urea derivative 1.05. Hydrolysis and further elaboration as described in Methods A/B provided the target compounds 1.14.
- BocHN 10.05 10.06
- the reaction mixture was concentrated in vacuo and diluted with aq. HCl (1 M, 200 mL) and extracted into CH 2 CI 2 (3x200 mL).
- Step 9 BocHN 10.09 10.10
- a solution of the acid 10.09 (from above) in CH 2 CI 2 (50 mL) and DMF (25 mL) was treated with NH 4 CI (2.94 g, 55.5 mmol), EDCI (3.15 g, 16.5 mmol), HOOBt (2.69 g, 16.5 mmol), and NMM (4.4 g, 44 mmol).
- the reaction mixture was stirred at room temperature for 3 d.
- the solvents were removed under vacuo and the residue was diluted with aq. HCl (250 mL) and extracted with CH2CI2.
- the combined organic layers were washed with aq. Sat'd.
- 10.10 can also be obtained directly by the reaction of 10.06 (4.5 g, 17.7 mmol) with aq. H 2 0 2 (10 mL), LiOH»H 2 0 (820 mg, 20.8 mmol) at 0 °C in 50 mL of CH 3 OH for 0.5 h.) Step 10.
- Compound 12.01 (Compound 12.01 was obtained commercially or can be synthesized using similar chemistry as outlined for the synthesis of 10.11 using bromomethyl cyclopropane instead of bromomethylcyclobutane) was converted to the required material 12.02 using essentially the procedures described for Intermediate 10.11, Steps 3-8.
- Step 2 13.03 .04 To a stirred solution of compound 13.03 (240 g, 1.35 mol) in acetic acid (1.25 L) was added 10% Pd/C (37 g). The resulting solution was hydrogenated at 59 psi for 3 hrs and then at 60 psi overnight. The acetic acid was then evaporated and azeotroped 3 times with toluene, then triturated with MeOH and ether. The solution was then filtered and azeotroped twice with toluene to afford 13.04 as an off white solid (131 g, 0.891 mol, 66%). Step 3
- the amino ester 20.01 was prepared following the method of R. Zhang and J.
- Boc group was cleaved by the reaction of the Boc-protected amino acid with methanolic HCl.
- Step l X ⁇ C0 2 H *- ⁇ N ⁇ C0 2 tBu I i Boc Boc 21.02 21.03
- ⁇ /-Boc-3,4-de ⁇ ydroproline 21.02 5.0 g, 23.5 mmol
- di-tert-butyl dicarbonate 7.5 g, 34.4 mmol
- 4-N,N- dimethylaminopyridine 0.40 g, 3.33 mmol
- triethylamine 5.0 m L, 35.6 mmol
- the carbamate 22.05 (8.81 g; 28.4mmol) was dissolved in acetonitrile (45ml) and the solution was. cooled to -40°C under an atmosphere of nitrogen. Pyridine (6.9ml; 85.3mmol) followed by nitrosium tetrafluoroborate (6.63g; 56.8mmol) were added and the resulting reaction mixture maintained below 0°C until TLC indicated that no starting material remained (approx. 2.25h.). Pyrrolidine (20ml; 240mmol) was added and the cooling bath was withdrawn and stirring was continued at room temperature for 1 hi . and then the volatiles were removed under reduced pressure. The residue was quickly passed through a pad of silica gel to provide a yellow oil.
- Hunigs base (4.5ml; 25.8mmol) was added to a mixture of N-Boc-L-fert-Leu-OH (1.76g; 7.6mmol), The crude pyrrolidine and HATU (2.89g; 7.6mmol) in an ydrous dichloromethane (50ml) at -60°C, under an atmosphere of nitrogen. The resulting reaction was allowed to come to room temperature slowly, overnight. EtOAc was added and the yellow solution was washed with dil. aq. HCl, sat. aq. sodium bicarbonate, water, brine. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EtOAc:hexanes (1 :3) to give the desired amide 22.09 (2.00g).
- the product 23.04 from the preceding step (2.7 g, 8.16 mmoL) was dissolved in dioxane (20 mL) and treated with freshly prepared 1N LiOH (9 mL). The reaction mixture was stirred at ambient temperature under N 2 for 20 h. The reaction mixture was taken in EtOAc and washed with H 2 0. The combined aqueous phase was cooled to 0°C and acidified to pH 1.65 using 1 N HCl. The turbid mixture was extracted with EtOAc (2 x 100 mL).
- Step 5 To a solution of the product 23.06 from preceding step (1.9g) in MeOH (40 mL) was treated with excess of CH 2 N 2 / Et 2 0 solution and stirred for overnight.
- Step 3 50.04 50.05
- the alcohol 50.04from above was dissolved in methylene chloride (400 mL) and cooled to 0°C under nitrogen atmosphere.
- PCC (22.2 g) was added in portions and the reaction mixture was slowly warmed to room temperature over 16 h.
- the reaction mixture was diluted with diethyl ether (500 mL) and filtered through a pad of celite. The filtrate was concentrated and the residue was taken in diethyl ether (500 mL). This was passed through a pad of silica gel and the filtrate was concentrated to provide the aldehyde 50.05 which was carried forward without further purification.
- the aldehyde 50.05 from above was converted to the desired material 50.01 using essentially the method of Chakraborty et. al (Tetrahedron, 1995, 51(33), 9179-90).
- 10001a 10001b The amine, 10001a, (C. A. Busacca et al, Tetrahedron: Asymmetry; (2000) 9 1907) (1.5 g, 6.9 mmol, 1 equiv.) was dissolved in dry dichloromethane 20 ml) and cooled to -78 °C. Added 3 ml (3 equiv.) of Et 3 N followed by the slow addition of dimethylsulfamyl chloride (1.5 eq., Sigma- Aldrich) dissolved in DCM. The temperature was kept at -78 °C until the addition is complete and then stirred overnight allowing it to raise to room temperature . Diluted with methylene chloride and washed with water, aq.
- 10001d 10003b 10003 To a solution of ammonium salt, 10001d, (20 mg, 0.073mmol, 1 equiv.) in DCM (5 ml) was added DIPEA (6 equiv.) at ice temperature was added isocyanate 10003b (1 equiv, 0.073 mmol, 3.66 mL of 0.02M soln) under N 2 atm. and stirred for 30 min at ice temperature and 90 min at room temperature. Quenched with citric acid and extracted with EtOAc and washed with brine. Dried over anhydrous sodium sulfate, filtered and evaporated off the solvent.
- Step B 10001a 10004c To 0.350g (1.62mmol) of 10001a in 10mL CH 2 CI 2 was added 0.23 mL (1.62mmol) of Et 3 N, then 0.446g (2.42mmol) of 10004b in 5 mL CH 2 CI 2 drop wise at rt. The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with EtOAc, washed with a solution of aq. NH 4 CI and brine. The organic layers was dried over MgS ⁇ 4 , filtered, concentrated in vacuo and purified by silica gel chromatography with 6- 24% EtOAc in Hexane to yield 0.353g of product. Yield 60%.
- Step C .HCI 10004C 10004d
- 2ml 8 mmol of 4M HCl (in dioxane)
- the reaction mixture was concentrated to dryness in vacuo to give 32mg of 2004d. Yield 100%.
- the conversion of 10004d to 10004 was identical to step B. in preparative example 3 Synthesis of compound of formula 10003.
- Example 5 Synthesis of compound of Formula 10005
- Step A 10004c 10005a To a solution of 0.275 g (0.76mmol) of 10004c in DMF was added 0.369g (1.13mmol) of Cs 2 C0 3 and 0.085mL (1.37mmol) of Mel at 0 °C. The reaction was stirred at rt. overnight. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried, concentrated in vacuo and the residue was purified by chromatography (Si0 2 8-32% EtOAc in hexane) to give 0.256 g of product 10005a. Yield 89%.
- Step B 10005a 10005b To a solution of 0.291 g (0.77mmol) of 10005a in flask was added
- Step C 10005b 10005c To 0.241 g (0.77mol) of 10005c in CH 2 CI 2 at 0° C was added 0.81 mL
- 11001a 11001b A solution of amide 11001a (Obtained by Cbz protection of tert- butylglycine -N-methyl amide obtained from commercial source: TCI-Japan) 18 g, 64.67 mmol) in toluene (200 mL) was treated with BH3-DMS (2 M soln. in THF, 65 mL, 130 mmol) and heated at 80° C for 3 h. The reaction mixture was cooled to rt. and treated carefully with aq. NaOH (2 M solution) and extracted into CH2CI2 (3x200 mL). The combined organic layers were extracted with aq.
- 11001c 1 1001d A solution of 11001c (1.28 g, 3.22 mmol) in methanol (30 mL) was treated with palladium hydroxide (200 mg, 10% wt/C) and hydrogenated at 60 psi for 3 h. The reaction mixture was filtered through a plug of celite ® and the filtrate was concentrated in vacuo. The residue was directly used in further reaction without purification.
- 11001e 11001 A solution of 11001e (50 mg, 0.075 mmol) in toluene (3 mL) and DMSO (3 mL) was treated with EDCI (134 mg, 0.703 mmol), and dichloroacetic acid (45.3 mg, 0.351 mmol, 30 ⁇ L) and stirred at rt. for 3 h.
- the reaction mixture was diluted with CH2CI2 (60 mL) and washed with aq. saturated NaHC ⁇ 3 (30 mL), aq.
- 11002b 11002c A solution of 11002b (279 mg, 0.52 mmol) in 4 M HCl dioxane was stirred at rt for 2 h and concentrated in vacuo. The residue was used in further reaction as it is.
- the ammonium salt (274 mg, 0.58 mmol) was dissolved in CH2CI 2 :DMF (1 :1) and cooled to 0 °C.
- the reaction mixture was treated with 4 eq of Et3N ( 233 mg, 2.33 mmol) and 2 eq of 2-pyridinesulfonyl chloride (248 mg, 1.2 mmol) and stirred at rt overnight. The reaction mixture was washed with saturated NaHC ⁇ 3, and the organic layer was extracted with CH2CI2.
- 11002c (240 mg, 0.41 mmol) was dissolved in THF and H2O (3:1) and treated with 2.5 eq of LiOH « H2 ⁇ .
- the reaction mixture was treated with MeOH until the solution turns homogeneous.
- the reaction mixture was stirred at rt for approximately 3 hr.
- the reaction mixture was treated with 1 M aq HCl and concentrated in vacuo.
- the aqueous layer was extracted with CH2CI2, dried with MgS04, filtered, and concentrated in vacuo.
- the crude was used in further couplings without any purification.
- the acid (179 mg, 0.32 mmol) was dissolved in 1 :1 CH2CI2/DMF and cooled to OOC.
- the reaction mixture was treated with 1.3 eq of deprotected 11.01 (11.01 was deprotected by dissolving (200 mg, 0.61 mmol) in 10 mL of TFA and 3 mL of Me 2 S and standing for 3h.
- the reaction mixture was concentrated in vacuo and used as it is in further couplings) (238 mg, 0.41 mmol ) 3.5 eq of NMM (112 mg 1.1 mmol), and 1.5 eq of HATU (180 mg, 0.47 mmol), and stored in the freezer ( ⁇ 0 ° ) overnight.
- the reaction mixture was concentrated under high vacuum, and the residue was treated with saturated NaHC03.
- the aqueous layer was extracted with CH2CI2, dried with MgS04, filtered, and concentrated in vacuo.
- 11002c 11003a A solution of ammonium salt 11002c (880 mg, 1.86 mmol) in dry methylene chloride was cooled to 0 °C and treated with triethylamine (0.5 mL, 3.71 mmol) and 2-thiophenesulfonyl chloride (678 mg, 3.71 mmol) and stirred at 0 °C for 48 h. The reaction mixture was taken in methylene chloride and the organic layer was washed with aq. HCl (1 M soln.), and brine.
- 11003a 11003b A solution of 11003a (1.2 g, 2.22 mmol) in THF/H 2 0 was treated with LiOH « H 2 0 and stirred at rt. for 3 h. The reaction mixture was acidified with 1 M aq. HCl and extracted with CH 2 CI 2 . The combined organic layers were dried (MgS0 ), filtered concentrated in vacuo and used as it is in the next step. A solution of acid (100 mg, 0.175 mmol) in dry CH2CI2 (4 mL) and
- 11004c 11004 Intermediate 11004c was converted to 11004 by coupling to intermediate 12.03 followed by Moffett oxidation identical to the procedures described in preparative example-6 of synthesis of 11001, Step D and Step E.
- Compounds shown in the following Table 2 were synthesized using similar reactions as shown in Examples above. Range of Ki* Indicated A ⁇ 75 nM; 75 ⁇ B ⁇ 250 nM; O250 nM. Table 2
- Step A H XNHBOS ⁇ N ⁇ NHt ⁇
- Step A 12002a 12002b A solution 12002a (Gregory, H. et al.; J. Chem. Soc. 1968; 531) (11.62 g, 42.08 mmol) in dry toluene was treated with BH 3 « DMS (-10 M soln, 6.3 mL) and heated at 70°C overnight. The reaction mixture was cooled to rt and quenched with aq. NaOH and extracted with CH 2 CI2. The combined organic layers were extracted with brine and concentrated in vacuo to yield 12002b 8.77 g (80%).
- Step B 12002a 12002b A solution 12002a (Gregory, H. et al.; J. Chem. Soc. 1968; 531) (11.62 g, 42.08 mmol) in dry toluene was treated with BH 3 « DMS (-10 M soln, 6.3 mL) and heated at 70°C overnight. The reaction mixture was cooled to rt and quenched with aq. NaOH and extracted with
- 12002b 12002c A solution of 12002b (2 g,.7.24 mmol) in methylene chloride was ; treated with pyridine (7.9 g, 100 mmol), and . rnethanesulfonyl chloride (1.24 g, 1.0.86 mmol) and stirred at rt. for 24 h. The reaction mixture was washed wit aq HCl, saturated NaHC0 3 and brine. The organic layer was dried (MgS0 4 ) filtered, concentrated in vacuo and purified by chromatography (Si0 2 , acetone/Hexanes 1:2) to yield 12002c. Step C:
- a solution of 12002c (465 mg, 1.37 mmol) in methanol was treated with palladium on carbon and hydrogenated for 2 h at 50 psi.
- the reaction mixture was filtered through a plug of celite ® and concentrated in vacuo to isolate the deprotected amine which was used in the next reaction without further purification.
- a solution of deprotected amine in CH 2 CI 2 /DMF (1 :1) was treated with 4-nitrophenylcarbamate 1.16 (612 mg, 1.37 mmol), NMM (548 mg, 5.48 mmol) and stirred at rt. for 12 h.
- the reaction mixture was concentrated in vacuo diluted with CH2CI2 (200 L) and washed with aq.
- the acid, 13001a, (5 g, 21.6 mmol, 1 equiv. Fluka) and methyl amine hydrochloride (1.2 equiv., 25.92 mmol) were dissolved in dry N, N-dimethyl formamide (20 ml) and cooled to 0 ° C.
- Step C H JWOC ⁇ l NHBoo 13001c 13001d
- triethylamine 3 equiv.
- acetyl chloride 3 equiv.
- Step D 13002b 13002c To the methyl ester, 13002b (270 mg, 0.562 mmol, 1 equiv.) in dioxane ( 10 ml) was added a solution of LiOH (10 equiv., 6 mL of 1N soln. in water) and stirred overnight. Quenched with 1N HCl and extracted with EtOAC. Washed with brine and dried over anhydrous sodium sulfate. Filtered and evaporated off the solvent, crude yield 260 mg (99 %). Step E:
- 13002c 13002 To the ammonium salt, 10.11 (16.06 mg, 0.077mmol, 1.2 equiv.) in DCM (10 ml) was added 13002 c (30 mg, 0.064 mmol, 1 equiv.) and cooled to - 20 ° C and added HATU (1.2 equiv., 0.077 mmol, 29.37 mg) followed by
- Step A HCbz 14001a 14001b
- 14001a (10.0 g, 40.0 mmol Indofine chemicals) in toluene (150 mL) was treated with BH 3 *DMS ( ⁇ 2 M, 40 mL) and heated at 90 °C overnight.
- the reaction mixture was cooled to 0° C and diluted with 2 M aq. NaOH.
- the reaction mixture was heated at 90 °C for 15 min.
- the aqueous layer was extracted with CH 2 CI 2 and the combined organic layers were dried (MgS0 4 ) filtered concentrated in vacuo to yield 11 g of 14001b.
- Step B 14001b 14001c
- a solution of amine 14001b (10 g, 42.0 mmol) in CH 2 CI 2 /DMF (1 :5) was cooled to -78 °C and treated with di-terf-butyldicarbonate (13.8 g, 63 mmol).
- the reaction mixture was stirred at rt for 48 h and diluted with aq. 1 M HCl and extracted with EtOAc.
- the combined organic layer was washed with aq. NaHC0 3 , brine, dried, filtered and concentrated in vacuo.
- the residue was purified by chromatography (Si0 2 , EtOAc/Hexanes 1 :3) to yield 4 g of Boc protected compound.
- Step B 14002a 14002 Intermediate 14002a was converted to 14002 by coupling to intermediate 10.11 followed by Moffett oxidation identical to the procedures described in preparative example 6 of synthesis of 11001, Step D and Step E. Compounds shown in the following Table 5 were synthesized using similar reactions as shown in Examples above. Ki* Range Indicated A ⁇ 75 nM; 75 ⁇ B ⁇ 250 nM; O250 nM.
- Table 5A Table 5A
- the present invention relates to novel HCV protease inhibitors.
- This utility can be manifested in their ability to inhibit the HCV NS2/NS4a serine protease.
- a general procedure for such demonstration is illustrated by the following in vitro assay.
- Assay for HCV Protease Inhibitory Activity Spectrophotometric Assay: Spectrophotometric assay for the HCV serine protease can be performed on the inventive compounds by following the procedure described by R. Zhang et al, Analytical Biochemistry, 270 (1999) 268-275, the disclosure of which is incorporated herein by reference.
- the assay based on the proteolysis of chromogenic ester substrates is suitable for the continuous monitoring of HCV NS3 protease activity.
- Reagents for peptide synthesis were from Aldrich Chemicals, Novabiochem (San Diego, California), Applied Biosystems (Foster City, California) and Perseptive Biosystems (Framingham, Massachusetts). Peptides are synthesized manually or on an automated ABI model 431 A synthesizer (from Applied Biosystems).
- UV/VIS Spectrometer model LAMBDA 12 was from Perkin Elmer (Nor alk, Connecticut) and 96-well UV plates were obtained from Corning (Corning, New York).
- the prewarming block can be from USA Scientific (Ocala, Florida) and the 96-well plate vortexer is from Labline Instruments (Mel rose Park, Illinois).
- Spectramax Plus microtiter plate reader with monochrometer is obtained from Molecular Devices (Sunnyvale, California).
- Enzyme Preparation Recombinant heterodimeric HCV NS3/NS4A protease (strain 1a) is prepared by using the procedures published previously (D. L. Sali et al, Biochemistry, 37 (1998) 3392-3401 ). Protein concentrations are determined by the Biorad dye method using recombinant HGV protease standards previously quantified by amino acid analysis.
- the enzyme storage buffer 50 mM sodium phosphate pH 8.0, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside and 10 mM DTT
- the assay buffer 25 mM MOPS pH 6.5, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside, 5 ⁇ M EDTA and 5 ⁇ M DTT
- Substrate Synthesis and Purification The synthesis of the substrates is done as reported by R. Zhang et al, (ibid.) and is initiated by anchoring Fmoc-Nva- OH to 2-chlorotrityl chloride resin using a standard protocol (K. Barios et al, Int. J. Pept. Protein Res., 37 (1991), 513-520). The peptides are subsequently assembled, using Fmoc chemistry, either manually or on an automatic ABI model 431 peptide synthesizer.
- the N-acetylated and fully protected peptide fragments are cleaved from the resin either by 10% acetic acid (HOAc) and 10% trifluoroethanol (TFE) in dichloromethane (DCM) for 30 min , or by 2% trifluoroacetic acid (TFA) in DCM for 10 min.
- the combined filtrate and DCM wash is evaporated azeotropically (or repeatedly extracted by aqueous Na2CO3 solution) to remove the acid used in cleavage.
- the DCM phase is dried over Na2S ⁇ 4 and evaporated.
- the ester substrates are assembled using standard acid-alcohol coupling procedures (K. Holmber et al, Acta Chem. Scand., B33 (1979) 410- 5 412).
- Peptide fragments are dissolved in anhydrous pyridine (30-60 mg/ml) to which 10 molar equivalents of chromophore and a catalytic amount (0.1 eq.) of para-toluenesulfonic acid (pTSA) were added.
- pTSA para-toluenesulfonic acid
- Dicyclohexylcarbodiimide (DCC, 3 eq.) is added to initiate the coupling reactions.
- Product formation is monitored by HPLC and can be found to be complete following 12-72 hour 0 reaction at room temperature. Pyridine solvent is evaporated under vacuum and further removed by azeotropic evaporation with toluene.
- the peptide ester is deprotected with 95% TFA in DCM for two hours and extracted three times with anhydrous ethyl ether to remove excess chromophore.
- the deprotected substrate is purified by reversed phase HPLC on a C3 or C8
- HCV protease assays are performed at 30°C using a 200 ⁇ l reaction mix in a 96-well microtiter plate. Assay buffer conditions (25 mM MOPS pH 6.5, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside, 5 ⁇ M
- EDTA and 5 ⁇ M DTT are optimized for the NS3/NS4A heterodimer (D. L. Sali et al, ibid.)).
- 150 ⁇ l mixtures of buffer, substrate and inhibitor are placed in wells (final concentration of DMSO ⁇ 4 % v/v) and allowed to preincubate at 30 °C for approximately 3 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007500946A JP2007525510A (en) | 2004-02-27 | 2005-02-24 | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
RU2006134005/04A RU2006134005A (en) | 2004-02-27 | 2005-02-24 | NEW COMPOUNDS OPERATING AS NS3 SERIN PROTEASE INHIBITORS HEPATITIS C VIRUS |
BRPI0508095-9A BRPI0508095A (en) | 2004-02-27 | 2005-02-24 | compounds as inhibitors of hepatitis c virus ns3 serine protease |
CA002557247A CA2557247A1 (en) | 2004-02-27 | 2005-02-24 | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
EP05723589A EP1748983A2 (en) | 2004-02-27 | 2005-02-24 | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
AU2005222055A AU2005222055A1 (en) | 2004-02-27 | 2005-02-24 | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
IL177545A IL177545A0 (en) | 2004-02-27 | 2006-08-17 | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
NO20064356A NO20064356L (en) | 2004-02-27 | 2006-09-26 | Compounds as inhibitors of hepatitis C virus NS3 erin protease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54850704P | 2004-02-27 | 2004-02-27 | |
US60/548,507 | 2004-02-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005087721A2 true WO2005087721A2 (en) | 2005-09-22 |
WO2005087721A3 WO2005087721A3 (en) | 2005-11-10 |
Family
ID=34962171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/005772 WO2005087721A2 (en) | 2004-02-27 | 2005-02-24 | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
Country Status (16)
Country | Link |
---|---|
US (3) | US7192957B2 (en) |
EP (1) | EP1748983A2 (en) |
JP (1) | JP2007525510A (en) |
KR (1) | KR20060127162A (en) |
CN (1) | CN1946691A (en) |
AR (1) | AR047902A1 (en) |
AU (1) | AU2005222055A1 (en) |
BR (1) | BRPI0508095A (en) |
CA (1) | CA2557247A1 (en) |
EC (1) | ECSP066795A (en) |
IL (1) | IL177545A0 (en) |
NO (1) | NO20064356L (en) |
RU (1) | RU2006134005A (en) |
TW (1) | TW200602037A (en) |
WO (1) | WO2005087721A2 (en) |
ZA (1) | ZA200607104B (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130687A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
WO2006130554A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
WO2006130607A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
WO2007139585A1 (en) * | 2006-05-31 | 2007-12-06 | Schering Corporation | Controlled-release formulation |
WO2008125486A1 (en) | 2007-04-11 | 2008-10-23 | Clariant Specialty Fine Chemicals (France) | Process of deacetalisation of alpha aminoacetals |
WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2010080874A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7897622B2 (en) | 2006-08-17 | 2011-03-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2364984A1 (en) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2428204A3 (en) * | 2006-12-07 | 2012-07-04 | Schering Corporation | pH sensitive matrix formulation |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8293915B2 (en) | 2007-02-09 | 2012-10-23 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
NZ563365A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
WO2007106317A2 (en) * | 2006-03-03 | 2007-09-20 | Schering Corporation | Pharmaceutical combinations of hcv-protease and -ires inhibitors |
US20080045530A1 (en) * | 2006-04-11 | 2008-02-21 | Trixi Brandl | Organic Compounds and Their Uses |
JP5167244B2 (en) * | 2006-04-11 | 2013-03-21 | ノバルティス アーゲー | HCV / HIV inhibitors and their use |
EP2007788A2 (en) * | 2006-04-11 | 2008-12-31 | Novartis AG | Hcv inhibitors |
CN104016970A (en) * | 2007-10-10 | 2014-09-03 | 诺华股份有限公司 | Spiropyrrolidines and their use against HCV and HIV infection |
NZ587133A (en) * | 2008-02-04 | 2012-10-26 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitor compounds for treating an HCV infection |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
JP5690286B2 (en) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス,インコーポレイテッド | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8980920B2 (en) | 2009-05-29 | 2015-03-17 | Merck Sharp & Dohme Corp. | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
JP2013514982A (en) | 2009-12-18 | 2013-05-02 | イデニク プハルマセウティカルス,インコーポレイテッド | 5,5-condensed arylene or heteroarylene hepatitis C virus inhibitor |
WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
US8609635B2 (en) | 2010-03-09 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
EP2598149A4 (en) | 2010-07-26 | 2014-09-10 | Merck Sharp & Dohme | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
AU2011314168A1 (en) | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9061041B2 (en) | 2011-04-13 | 2015-06-23 | Merck Sharp & Dohme Corp. | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
CA3091142C (en) * | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2023133174A1 (en) * | 2022-01-07 | 2023-07-13 | Merck Sharp & Dohme Llc | Protease inhibitors for treating or preventing coronavirus infection |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318216A1 (en) | 1987-11-18 | 1989-05-31 | Chiron Corporation | NANBV diagnostics and vaccines |
US5712145A (en) | 1990-04-04 | 1998-01-27 | Chiron Corporation | Hepatitis C virus protease |
WO2001074768A2 (en) | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE132182T1 (en) | 1989-02-01 | 1996-01-15 | Asahi Glass Co Ltd | AZEOTROPIC OR AZEOTROP-LIKE COMPOSITION BASED ON CHLOROFLUOROHYDROCARBONS |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
AR022061A1 (en) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH . |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
JP2001049593A (en) | 1999-07-22 | 2001-02-20 | E I Du Pont De Nemours & Co | Fiber paper comprising wholly aromatic synthetic fiber and method for producing the same and laminate |
IL151934A0 (en) | 2000-04-05 | 2003-04-10 | Schering Corp | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
WO2001081325A2 (en) | 2000-04-19 | 2001-11-01 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
RU2355700C9 (en) | 2000-07-21 | 2010-03-20 | Шеринг Корпорейшн | Novel peptides as inhibitors of hepatitis c virus ns3 serine protease |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
US7169760B2 (en) | 2000-07-21 | 2007-01-30 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR034127A1 (en) | 2000-07-21 | 2004-02-04 | Schering Corp | IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
MXPA03005219A (en) | 2000-12-12 | 2003-09-25 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus. |
WO2003035060A1 (en) | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
DE60329367D1 (en) * | 2002-01-23 | 2009-11-05 | Schering Corp | USE IN THE FIGHT AGAINST HEPATITIS C VIRUS INFECTION |
ATE438622T1 (en) * | 2004-02-27 | 2009-08-15 | Schering Corp | 3,4-(CYCLOPENTYL)CONDENSED PROLINE COMPOUNDS AS INHIBITORS OF THE NS3 SERINE PROTEASE OF THE HEPATITIS C VIRUS |
CA2557304C (en) * | 2004-02-27 | 2013-08-06 | Schering Corporation | Ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
-
2005
- 2005-02-24 EP EP05723589A patent/EP1748983A2/en not_active Withdrawn
- 2005-02-24 TW TW094105621A patent/TW200602037A/en unknown
- 2005-02-24 US US11/065,509 patent/US7192957B2/en not_active Expired - Fee Related
- 2005-02-24 RU RU2006134005/04A patent/RU2006134005A/en not_active Application Discontinuation
- 2005-02-24 AU AU2005222055A patent/AU2005222055A1/en not_active Abandoned
- 2005-02-24 WO PCT/US2005/005772 patent/WO2005087721A2/en active Search and Examination
- 2005-02-24 JP JP2007500946A patent/JP2007525510A/en not_active Ceased
- 2005-02-24 KR KR1020067017295A patent/KR20060127162A/en not_active Application Discontinuation
- 2005-02-24 BR BRPI0508095-9A patent/BRPI0508095A/en not_active IP Right Cessation
- 2005-02-24 CN CNA2005800127105A patent/CN1946691A/en active Pending
- 2005-02-24 CA CA002557247A patent/CA2557247A1/en not_active Abandoned
- 2005-02-25 AR ARP050100720A patent/AR047902A1/en unknown
-
2006
- 2006-08-17 IL IL177545A patent/IL177545A0/en unknown
- 2006-08-24 ZA ZA200607104A patent/ZA200607104B/en unknown
- 2006-08-25 EC EC2006006795A patent/ECSP066795A/en unknown
- 2006-09-26 NO NO20064356A patent/NO20064356L/en not_active Application Discontinuation
- 2006-10-03 US US11/542,156 patent/US7759499B2/en not_active Expired - Fee Related
- 2006-10-03 US US11/542,228 patent/US7718691B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318216A1 (en) | 1987-11-18 | 1989-05-31 | Chiron Corporation | NANBV diagnostics and vaccines |
WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
US5712145A (en) | 1990-04-04 | 1998-01-27 | Chiron Corporation | Hepatitis C virus protease |
WO2001074768A2 (en) | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130687A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
WO2006130554A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
WO2006130607A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
WO2006130666A3 (en) * | 2005-06-02 | 2007-06-21 | Schering Corp | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2006130552A3 (en) * | 2005-06-02 | 2007-09-07 | Schering Corp | Methods of treating hepatitis c virus |
WO2006130607A3 (en) * | 2005-06-02 | 2007-09-13 | Schering Corp | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
WO2006130626A3 (en) * | 2005-06-02 | 2007-09-20 | Schering Corp | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
WO2006130687A3 (en) * | 2005-06-02 | 2007-09-20 | Schering Corp | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
WO2006130554A3 (en) * | 2005-06-02 | 2007-09-20 | Schering Corp | Methods of treating hepatitis c virus |
EP2364984A1 (en) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2366704A1 (en) | 2005-08-26 | 2011-09-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
WO2007120595A3 (en) * | 2006-04-11 | 2007-11-22 | Novartis Ag | Amines for the treatment of hcv |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
WO2007139585A1 (en) * | 2006-05-31 | 2007-12-06 | Schering Corporation | Controlled-release formulation |
US7897622B2 (en) | 2006-08-17 | 2011-03-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EP2428204A3 (en) * | 2006-12-07 | 2012-07-04 | Schering Corporation | pH sensitive matrix formulation |
US8293915B2 (en) | 2007-02-09 | 2012-10-23 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
WO2008125486A1 (en) | 2007-04-11 | 2008-10-23 | Clariant Specialty Fine Chemicals (France) | Process of deacetalisation of alpha aminoacetals |
US8609882B2 (en) | 2007-04-11 | 2013-12-17 | Clariant Speciality Fine Chemicals (France) | Process for deacetalisation of α aminoacetals |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8541402B2 (en) | 2007-12-19 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8912182B2 (en) | 2007-12-19 | 2014-12-16 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2010080874A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
Also Published As
Publication number | Publication date |
---|---|
KR20060127162A (en) | 2006-12-11 |
US20050288233A1 (en) | 2005-12-29 |
US7759499B2 (en) | 2010-07-20 |
CA2557247A1 (en) | 2005-09-22 |
AU2005222055A1 (en) | 2005-09-22 |
WO2005087721A3 (en) | 2005-11-10 |
ECSP066795A (en) | 2006-11-16 |
NO20064356L (en) | 2006-11-24 |
BRPI0508095A (en) | 2007-07-17 |
RU2006134005A (en) | 2008-04-10 |
TW200602037A (en) | 2006-01-16 |
US20070032434A1 (en) | 2007-02-08 |
EP1748983A2 (en) | 2007-02-07 |
US7718691B2 (en) | 2010-05-18 |
CN1946691A (en) | 2007-04-11 |
AR047902A1 (en) | 2006-03-01 |
IL177545A0 (en) | 2006-12-10 |
US7192957B2 (en) | 2007-03-20 |
ZA200607104B (en) | 2008-09-25 |
JP2007525510A (en) | 2007-09-06 |
US20070049536A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1939213B1 (en) | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | |
EP1737821B1 (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
EP1773868B1 (en) | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease | |
EP1730142B1 (en) | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus | |
US7759499B2 (en) | Compounds as inhibitors of hepatitis C virus NS3 serine protease | |
EP1797111B1 (en) | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease | |
EP1742913A1 (en) | Inhibitors of hepatitis c virus ns3/ns4a serine protease | |
EP1730165A1 (en) | Inhibitors of hepatitis c virus ns3 protease | |
WO2005087731A1 (en) | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | |
WO2005085197A1 (en) | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease | |
MXPA06009811A (en) | Compounds as inhibitors of hepatitis c virus ns3 serine protease | |
MXPA06009812A (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
MXPA06009809A (en) | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease | |
MXPA06009815A (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 549157 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 177545 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501630 Country of ref document: PH Ref document number: 2005222055 Country of ref document: AU Ref document number: 06082842 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2557247 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007500946 Country of ref document: JP Ref document number: 200607104 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3093/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067017295 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/009811 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2005222055 Country of ref document: AU Date of ref document: 20050224 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005222055 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005723589 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006134005 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580012710.5 Country of ref document: CN |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 1020067017295 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005723589 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0508095 Country of ref document: BR |